Injection Site Reactions on a GLP-1 Microdose: Redness, Lumps, Itching, and What the Label Data Shows
Injection site reactions on a GLP-1 microdose are usually small: a pink patch, an itchy spot, a bruise that fades in a few days. They are also one of the side effects people notice most, because they show up on the skin every week. Here is how often they happen on semaglutide and tirzepatide, what drives them, and which habits the evidence actually backs.
6-8%
INJECTION SITE REACTIONS ON TIRZEPATIDE 5 TO 15 MG VS 2% ON PLACEBO (ZEPBOUND LABEL)
1.4%
INJECTION SITE REACTIONS ON SEMAGLUTIDE VS 1.0% ON PLACEBO (WEGOVY LABEL)
3.55
RISK RATIO FOR INJECTION SITE REACTIONS WITH GLP-1 MEDICINES ACROSS 14 TRIALS (TAJ 2026)
Most talk about GLP-1 side effects centers on the stomach. Nausea, constipation and reflux get the headlines, and for good reason. But every dose of an injectable GLP-1 also passes through a small patch of skin and fat, and that patch can react.
This article pulls together the FDA prescribing information for Wegovy and Zepbound, a 2026 meta-analysis of randomized trials, a 2026 review of FDA adverse event reports, and a tirzepatide antibody analysis from the SURPASS program. One caveat up front: none of these sources tested sub-label microdose protocols, so the numbers describe standard doses. Where the evidence runs out, this article says so.
Key takeaways
- •A 2026 meta-analysis of 14 randomized trials (4,861 patients) found GLP-1 medicines raised the risk of injection site reactions versus comparators, with a risk ratio of 3.55.
- •On the Zepbound label, injection site reactions occurred in 6% to 8% of people on tirzepatide versus 2% on placebo; on the Wegovy label, 1.4% on semaglutide versus 1.0% on placebo.
- •Tirzepatide injection site reactions were far more frequent in people who developed anti-drug antibodies (11.3%) than in those who did not (1%), though the antibodies did not change efficacy.
- •Both labels state that drug exposure is similar whether the injection goes into the abdomen, thigh or upper arm, so site choice can follow comfort and skin health.
- •Rotating sites is the best-supported prevention habit; in 430 insulin users, lipohypertrophy affected 64.4% overall but only 5% of those who rotated correctly.
How common are injection site reactions on GLP-1 medicines?
Injection site reactions are clearly more common on GLP-1 medicines than on placebo, but they remain a minority experience. The best pooled estimate comes from Taj and colleagues, who published a meta-analysis in Diabetes, Obesity and Metabolism in 2026. Across 14 randomized trials with 4,861 patients and 396 injection site events, GLP-1 medicines carried a risk ratio of 3.55 (95% confidence interval 2.35 to 5.36) compared with comparators.
A risk ratio of 3.55 sounds dramatic, so the absolute numbers matter. The product labels give them. The tirzepatide label for Zepbound reports injection site reactions in 6% of people on 5 mg and 8% on both 10 mg and 15 mg, against 2% on placebo. That pooled analysis covered 630, 948 and 941 people on the three doses.
Tirzepatide: injection site reactions by dose (% of patients)
Zepbound prescribing information, pool of Studies 1 and 2 (adults with obesity or overweight).
The dose pattern is worth a second look. The jump from placebo to the lowest tirzepatide dose is bigger than the jump between doses, and 10 mg and 15 mg sit level. That hints that being exposed to the drug at all matters more than how much of it is injected. Still, no trial has reported injection site reactions below 5 mg of tirzepatide, so whether a microdose behaves like 5 mg or like placebo is not established.
Does semaglutide cause fewer injection site reactions than tirzepatide?
On paper, semaglutide shows a lower rate of injection site reactions than tirzepatide. The Wegovy label reports them in 1.4% of adults on semaglutide versus 1.0% on placebo, listing itching, redness, inflammation, induration and irritation. The gap between drug and placebo is small.
Injection site reactions on each label: drug versus its own placebo group (%)
Wegovy and Zepbound prescribing information. Separate trial programs, so this is an indirect comparison.
- On drug
- On placebo
Real-world reporting points the same way. Elgindi and Petronic-Rosic reviewed 442,567 GLP-1 reports in the FDA Adverse Event Reporting System for Clinics in Dermatology in 2026. Skin and injection-site reactions made up 137,412 of them (31.0%), the third most common category overall.
Share of FDA adverse event reports that were skin or injection-site reactions, by drug (%)
Elgindi D, Petronic-Rosic V, Clin Dermatol 2026. Spontaneous reports show reporting patterns, not true incidence.
Exenatide led at 53.1%, followed by dulaglutide (33.5%), tirzepatide (32.6%), liraglutide (17.1%), semaglutide (12.2%) and lixisenatide (6.9%). The Taj meta-analysis also flagged exenatide and dulaglutide for injection-site bleeding signals. Spontaneous reports depend on who bothers to file them, so they cannot give a true rate, but the ranking lines up with the labels: semaglutide sits toward the gentle end, tirzepatide higher.
What does a GLP-1 injection site reaction look like?
A GLP-1 injection site reaction usually looks like a small area of redness, itching, tenderness or bruising around the spot where the needle went in. The Zepbound label groups bruising, redness, itching, pain and rash under this heading. The Wegovy label adds inflammation, irritation and induration, which is a firm, slightly raised patch under the skin.
The 2026 FDA-report review describes the same core list (pain, bleeding, redness, bruising, a lump or mass, itching and swelling) plus less common findings such as altered skin sensation, nodules and granulomatous reactions. Elgindi and Petronic-Rosic concluded that most reactions were mild to moderate and generally handled without stopping treatment.
Firm lumps that linger for weeks are a different story from a red spot that fades in a day or two. Repeated injections into the same patch can cause lipodystrophy, which the Zepbound instructions describe as "pits in skin or thickened skin," and localized cutaneous amyloidosis, described as "skin with lumps." Both are linked to site overuse rather than to a single dose, and both are discussed in the rotation section below. For wider skin changes during weight loss, see our piece on skin health and collagen on a GLP-1.
Why do some people react and others do not?
Anti-drug antibodies are the clearest known reason some people get injection site reactions on tirzepatide and others do not. The body sometimes treats a peptide drug as foreign and makes antibodies to it. Mullins and colleagues analyzed this across 7 SURPASS trials in 5,025 people with type 2 diabetes for the Journal of Clinical Endocrinology and Metabolism.
Treatment-emergent antibodies appeared in 51.1% of people on tirzepatide, at similar rates across doses. Neutralizing antibodies were rare, at 1.9% and 2.1% against activity at the two receptors. Antibody status had no effect on how tirzepatide was absorbed or how well it worked. It did change the side effect picture: more antibody-positive patients had hypersensitivity or injection site reactions, though most were nonserious.
Tirzepatide reactions by anti-drug antibody status (% of patients)
Zepbound prescribing information, pool of Studies 1 and 2.
- Developed antibodies
- No antibodies
The Zepbound label puts numbers on it. Injection site reactions occurred in 11.3% of tirzepatide users with antibodies and 1% of those without. Hypersensitivity reactions followed the same direction, 6.2% versus 3%, and the label notes most of those were skin reactions such as rash and itching. Nobody can choose whether they make antibodies, but it helps explain why a reaction can show up weeks into treatment after early doses were uneventful.
Does it matter where you inject a GLP-1?
For how much drug reaches the bloodstream, the injection site does not appear to matter. The Wegovy label says similar semaglutide exposure was achieved in the abdomen, thigh or upper arm, and that the site can be changed without adjusting the dose. The Zepbound label makes the same statement for tirzepatide, with the note that the back of the upper arm should be injected by another person.
That frees the choice up for comfort. Some people find the thigh less tender than the abdomen, others the reverse, and a spot that reacted last week is a good one to skip for a while. Our guide to GLP-1 timing and injection sites covers the day-of-week and meal questions that come with this.
How do you prevent lumps at a GLP-1 injection site?
Rotating the injection site with every dose is the best-supported way to prevent lumps and pitted or thickened skin. Both labels tell users to rotate, and the Zepbound vial instructions go further: change the spot within the chosen area for each dose "to reduce your risk of getting lipodystrophy" and localized cutaneous amyloidosis.
Direct GLP-1 data on rotation are thin, so the strongest evidence comes from insulin, which is injected far more often. Blanco and colleagues examined 430 insulin users in Diabetes and Metabolism in 2013. A nurse checked every injection site.
Lipohypertrophy at injection sites in insulin users (%)
Blanco M et al., Diabetes Metab 2013. Insulin, not GLP-1, users; shown for the rotation principle.
Lipohypertrophy affected 64.4% of the group, yet only 5% of those who rotated correctly. Among people who had it, 98% either did not rotate or rotated incorrectly. Risk also climbed when needles were reused more than 5 times. A weekly GLP-1 means far fewer injections than daily insulin, so the absolute risk is likely lower, but the principle carries over.
Practical points from the Zepbound instructions: avoid skin that has pits, is thickened or has lumps, and skip areas that are tender, bruised, scaly or hard, or scarred. With vials, use a new syringe and needle for each injection. People drawing small volumes from a vial will find more detail in our article on reconstitution, storage and dosing accuracy.
When is a skin reaction a sign of allergy?
A reaction that spreads beyond the injection spot, or that comes with swelling of the face, lips or throat, may be a hypersensitivity reaction rather than local irritation. The Zepbound label separates the two. In the pooled trials, immediate hypersensitivity reactions within one day of a dose occurred in 2.1% on tirzepatide versus 0.4% on placebo, and later reactions in 3.5% versus 2.7%.
Most of those were skin reactions such as rash and itching. Both labels also note that serious reactions, including anaphylaxis and angioedema, have been reported after approval. The Wegovy label tells users to stop the drug and promptly seek medical advice if one is suspected, and anyone with a prior serious hypersensitivity reaction to semaglutide should not use it.
A useful rule of thumb: a coin-sized red or itchy patch that fades within a few days is the common, local kind. Hives elsewhere on the body, breathing trouble, a swollen tongue or feeling faint is an emergency. A site that keeps growing, turns hot or drains needs a clinician to rule out infection. Our overview of whether microdosing Ozempic is safe covers the broader safety picture.
What does this mean for microdosing?
For people on low GLP-1 doses, the honest answer is that injection site reactions at microdoses have not been studied. Every rate in this article comes from standard label doses. The flat tirzepatide curve from 10 mg to 15 mg, and the strong antibody link, suggest that a smaller dose is not a guarantee of clear skin.
What does carry over is technique. Rotating sites, using a fresh needle, avoiding damaged skin and watching how a site looks the following day are all low-cost habits with a sound rationale. Many microdose protocols involve drawing small volumes from vials, which adds needle handling to the routine, so those habits matter at least as much as they do with a prefilled pen.
A small red or itchy patch is common and usually harmless. Rotation is the habit with the best evidence behind it, and any reaction that spreads or affects breathing is a reason to stop and get help.
Frequently asked questions
Are injection site reactions common on a GLP-1 microdose?
Injection site reactions are among the more common GLP-1 side effects, but they are usually mild. On the Zepbound label, 6% to 8% of people on tirzepatide had one versus 2% on placebo, and on the Wegovy label the figures were 1.4% versus 1.0%. No trial has measured injection site reactions at sub-label microdoses, so those rates are the closest guide available.
What does a GLP-1 injection site reaction look like?
The labels list redness, itching, pain, bruising, rash, swelling, inflammation and a firm patch called induration. A 2026 review of FDA reports added lumps or masses and bleeding at the site. Most of these reactions are mild to moderate and settle without stopping treatment.
Why does my tirzepatide injection site itch or turn red?
One clear factor is the immune system. On the Zepbound label, injection site reactions occurred in 11.3% of people who developed anti-tirzepatide antibodies versus 1% of those who did not. The antibodies did not change how well tirzepatide worked in the SURPASS trials, and most of the reactions were nonserious.
Is tirzepatide more likely than semaglutide to cause injection site reactions?
On the labels, tirzepatide shows a higher rate: 6% to 8% on Zepbound versus 1.4% on Wegovy, each against its own placebo group. These come from separate trials, so the comparison is indirect. In FAERS reports, skin and injection-site reactions made up 32.6% of tirzepatide reports versus 12.2% of semaglutide reports.
Does the injection site affect how well a GLP-1 works?
Not in a meaningful way, according to both labels. The Wegovy and Zepbound prescribing information each state that similar drug exposure was achieved in the abdomen, thigh or upper arm. That means site choice can be driven by comfort and skin health rather than absorption.
How do I prevent lumps at a GLP-1 injection site?
Rotate the injection site with every dose, including moving to a new spot within the same area. The Zepbound label says rotation reduces the risk of lipodystrophy and localized cutaneous amyloidosis. In a study of 430 insulin users, only 5% of those who rotated correctly had lipohypertrophy, compared with 64.4% of the group overall.
Should I reuse a syringe for compounded or vial GLP-1 doses?
No. The Zepbound label says to always use a new syringe and needle for each injection when using vials. In insulin users, lipohypertrophy risk rose significantly once needles were reused more than 5 times, which is another practical reason to use a fresh needle each time.
When is an injection site reaction a reason to call a doctor?
Swelling of the face, lips, tongue or throat, trouble breathing, a widespread rash or feeling faint needs urgent care, because anaphylaxis and angioedema have been reported with GLP-1 medicines. A site that keeps getting larger, hot, very painful or that drains also warrants a prompt check. Both labels say to stop the drug and seek medical advice if a serious hypersensitivity reaction is suspected.
Clinical references
- Taj S, Zuber M, Rashid M, Chhabra M, et al. Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70382
- Elgindi D, Petronic-Rosic V. Glucagon-like peptide-1 receptor agonist-associated injection site and dermatologic reactions. Clinics in Dermatology. 2026. doi:10.1016/j.clindermatol.2026.08.012
- Mullins GR, Hodsdon ME, Li YG, Anglin G, et al. Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies. Journal of Clinical Endocrinology and Metabolism. 2024. doi:10.1210/clinem/dgad532
- Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes and Metabolism. 2013. doi:10.1016/j.diabet.2013.05.006
- ZEPBOUND (tirzepatide) injection, prescribing information. Eli Lilly and Company. DailyMed
- WEGOVY (semaglutide) injection, prescribing information. Novo Nordisk. DailyMed
Medical disclaimer. This article is for general educational and informational purposes only. It is not medical advice and not a substitute for the clinician or pharmacist responsible for your care. Sub-label "microdose" regimens of GLP-1 medicines have not been tested in clinical trials, and the injection site reaction rates quoted here come from standard approved doses. Charts show values reported in the cited labels and studies. Seek emergency care for swelling of the face, lips, tongue or throat, trouble breathing, or a widespread rash after an injection.